As France's leading biocluster, Genopole is an incubator for cutting-edge projects in biotechnology. Located in the city of Évry, just south of Paris, Genopole provides a unique environment for scientists and entrepreneurs seeking to advance research and innovation.

Discover >


Genopole accompanies researchers, postdocs and start-up entrepreneurs through all the phases of their projects to ensure the best possible conditions for business development.

Discover >

Genopole’s citizens

Every day, at Genopole, researchers, entrepreneurs and students cross paths, share ideas and unite forces in a veritable melting pot for innovation.

Discover >


Giving wings to research and empowering employment in our community are cornerstones of Genopole's mission. Catch up on recent scientific advances, the accomplishments of our biotech actors and the events that enliven the biocluster.

Discover >

Innovate with us

Discover >

Cell Environment

Pépinière Genopole Enteprises
4 rue Pierre Fontaine
91000 Evry-Courcouronnes – France

Contact :

Radhia M’kacher : Présidente directrice générale
Web Site >
Cell Environment - Genopole's company Cell Environment - Genopole's company

Booster#Health / Well-being #Diagnostics

  • DNA damage
  • Repeated sequences
  • Unique sequences
  • Telomeres
  • Centromeres

Field of Activity

Cell Environment is a company focusing on DNA damage detection involving unique and repeated sequences such as telomere and centromere sequences.


Our academic research developed over 20 years reliable, sensitive and automated methods to detect DNA damage. Cell Environment was created to transfer these techniques into the clinics.


Cell Environment developed a high throughput genomic cytogenetic approach based on a very small amount of samples. This process associates telomere quantification to the analysis of chromosomal aberrations and the detection of chromosomal instability.

This approach is a break with the existent techniques. In order to transfer this approach in the clinics, we developed the kits of telomere and centromere staining as well as the software for automated analysis.


The first flagship products resulting from this innovation are

  1. telomere and centromere staining kits.
  2. development of three analysis software
  3. creation of an automated analysis platform.

A validation of the approach was performed against clinical cytogenetics. A patent has been filed. The company has been approved as an R&D provider since 2017.


Cell Environment has started the industrialization and commercialization phase and we are looking for partners for the distribution of kits and funds to make our solution more relevant.

  • Further information

    1 Patent

    Les forces :
    Automation of the detection of DNA damage involving unique and repeated sequences.
    Scientific soundness (more than 14 scientific publications) and collaborative networks.

    Le + innovation :
    The use of a small amount of samples.

Genopole’s Companies


In same field

CGenetix - Entreprise génopolitaine


CGenetix, is a medTech start-up developing in vitro medical diagnostic devices for the follow-up of transplant patients.

EndoGene.Bio - Genopole's Company


Research & development for an in vitro diagnostic tool for endometriosis

SafeInsight - Entreprise génopolitaine


SafeInsight seeks to provide a response to the growing concerns of consumers for the composition of the products they buy and accompanies manufacturers aiming to attentively circumscribe the problem of endocrine disruptors.

Floating Genes - entreprises génopolitaines

Floating Genes

Floating Genes develops diagnostic tools for use in liquid biopsies via the highly sensitive NGS detection of circulating tumor DNA.

Innovhem - Entreprise génopolitaine


Our mission is to improve the management of Red Blood Cell diseases and in particular Sickle Cell Disease

IntegraGen - Genopole's Company


IntegraGen’s mission is to translate molecular research to clinical practice through the identification of novel genetic biomarkers and the subsequent commercialization of molecular diagnostic tests based on these discoveries.

Enalees - Genopole Company 2024


Enalees conceives, develops and markets next-generation rapid molecular diagnosis tests for veterinarians, and furthermore screening tests for SARS-CoV-2.

View all >
With the support from
Région île de France